



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

24 January 2020
EMA/CAT/127341/2020
Inspections, Human Medicines Pharmacovigilance and Committees Division

Committee for Advanced Therapies (CAT)

Minutes of the meeting on 04-06 December 2019

Health and safety information

In accordance with the Agency's health and safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting.

Disclaimers

Some of the information contained in these minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CAT meeting reports once the procedures are finalised.

Of note, the minutes are a working document primarily designed for CAT members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

Official address Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands

For deliveries refer to www.ema.europa.eu/how-to-find-us

Send us a question via www.ema.europa.eu/contacts **Telephone** +31(0)88 781 6000

An agency of the European Union



Table of contents

1.	Introduction	6
1.1.	Welcome and declarations of interest of members, alternates and experts	6
1.2.	Adoption of agenda.....	6
1.3.	Adoption of the minutes	6
2.	Evaluation of ATMPs	6
2.1.	Opinions	6
2.2.	Oral explanations	6
2.3.	Day 180 list of outstanding issues	6
2.3.1.	Onasemnogene abeparvovec - Orphan - EMEA/H/C/004750	6
2.4.	Day 120 list of questions	7
2.5.	Day 80 assessment reports.....	7
2.6.	Update on ongoing initial applications.....	7
2.7.	New applications	7
2.7.1.	Autologous CD34+ cell enriched population that contains hematopoietic stem and progenitor cells transduced ex vivo using a lentiviral vector encoding the human arylsulfatase a gene - Orphan - EMEA/H/C/005321	7
2.8.	Withdrawal of initial marking authorisation application	7
2.9.	Re-examination of initial application procedures under Article 9(2) of Regulation No. 726/2004	7
2.10.	GMP and GCP inspections requests.....	7
2.11.	Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008.....	7
2.11.1.	Alofisel - darvadstrocel - Orphan - EMEA/H/C/004258/II/0010/G.....	8
2.11.2.	Kymriah - tisagenlecleucel - Orphan - EMEA/H/C/004090/II/0013/G.....	8
2.12.	Other Post-Authorisation Activities	8
2.12.1.	Kymriah - tisagenlecleucel - Orphan - EMEA/H/C/004090/X/0010.....	8
2.12.2.	Strimvelis - autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence - Orphan - EMEA/H/C/003854/ANX/004.2	9
2.12.3.	Zynteglo - autologous CD34+ cell enriched population that contains hematopoietic stem cells transduced with lentiglobin BB305 lentiviral vector encoding the beta-A-T87Q-globin gene - Orphan - EMEA/H/C/003691/REC/007	9
2.12.4.	Zynteglo - autologous CD34+ cell enriched population that contains hematopoietic stem cells transduced with lentiglobin BB305 lentiviral vector encoding the beta-A-T87Q-globin gene - Orphan - EMEA/H/C/003691/REC/008	9
3.	Certification of ATMPs	9
3.1.	Opinion.....	9
3.2.	Day 60 Evaluation Reports.....	9
3.3.	New Applications	10

4. Scientific Recommendation on Classification of ATMPs 10

4.1. New requests – Appointment of CAT Coordinator 10

- 4.1.1. Recombinant adeno-associated viral vector serotype 9 encoding a codon-optimised human aspartylglucosaminidase (AGA) transgene – 10
- 4.1.2. Adipose tissue derived mesenchymal stem cell , Alopecia - 10
- 4.1.3. Wharton’s Jelly derived mesenchymal stem cell , AMD - 10
- 4.1.4. Wharton’s Jelly derived mesenchymal stem cell , bone non-union - 10
- 4.1.5. Wharton’s Jelly derived mesenchymal stem cell , Chorioretinal disorders - 11
- 4.1.6. Wharton’s Jelly derived mesenchymal stem cell , Epidermolysis bullosa - 11
- 4.1.7. Adipose tissue derived mesenchymal stem cell , Hypertrophic scars - 11
- 4.1.8. Wharton’s Jelly derived mesenchymal stem cell , hypoxic-ischemic encephalopathy (HIE) - 11

4.2. Day 30 ATMP scientific recommendation 11

- 4.2.1. Autologous chondrocytes in suspension - H0005498 11
- 4.2.2. Autologous chondrocytes on a fibrinogen carrier – H0005525..... 12
- 4.2.3. MICs - Modulated immune cells – H0005515 12
- 4.2.4. Wharton’s Jelly derived mesenchymal stem cell , Adrenoleukodystrophy – H0005526 12
- 4.2.5. Wharton’s Jelly derived mesenchymal stem cell , Encephalopathy – H0005527..... 12
- 4.2.6. Wharton’s Jelly derived mesenchymal stem cell , Epilepsy – H0005528 13
- 4.2.7. Wharton’s Jelly derived mesenchymal stem cell , Osteoarthritis – H0005529..... 13
- 4.2.8. Wharton’s Jelly derived mesenchymal stem cell , Polyneuropathy – H0005530 13
- 4.2.9. Wharton’s Jelly derived mesenchymal stem cell , Spinal muscular atrophy – H0005531.... 13
- 4.2.10. Wharton’s Jelly derived mesenchymal stem cell , Spinocerebellar ataxia – H0005532..... 14

4.3. Day 60 revised scientific recommendation (following list of questions) 14

4.4. Finalisation of procedure 14

- 4.4.1. Recombinant adeno associated viral vector serotype 9 containing the human CLN6 gene Amicus – H0005491 14
- 4.4.2. Recombinant adeno associated viral vector serotype 9 containing the human CLN3 gene – H0005492..... 14
- 4.4.3. Wharton’s Jelly derived mesenchymal stem cell , Alopecia areata – H0005494 14
- 4.4.4. Wharton’s Jelly derived mesenchymal stem cell , Pervasive developmental disorder – H0005502..... 15
- 4.4.5. Wharton’s Jelly derived mesenchymal stem cell , Cerebral infarction – H0005503..... 15
- 4.4.6. Wharton’s Jelly derived mesenchymal stem cell , Development delay – H0005504..... 15
- 4.4.7. Wharton’s Jelly derived mesenchymal stem cell , Diabetes - H0005505 15
- 4.4.8. Wharton’s Jelly derived mesenchymal stem cell , Muscular dystrophy – H0005506 15
- 4.4.9. Wharton’s Jelly derived mesenchymal stem cell , Endometrial atrophy – H0005507 15
- 4.4.10. Wharton’s Jelly derived mesenchymal stem cell , Multiple sclerosis – H0005508 16
- 4.4.11. Wharton’s Jelly derived mesenchymal stem cell , Optic neuropathy – H0005509..... 16
- 4.4.12. Wharton’s Jelly derived mesenchymal stem cell , Premature ovarian failure – H0005510 .. 16

4.4.13.	Wharton’s Jelly derived mesenchymal stem cell , Retinitis pigmentosa – H0005511	16
4.4.14.	Wharton’s Jelly derived mesenchymal stem cell , Spina bifida – H0005512	16
4.4.15.	Wharton’s Jelly derived mesenchymal stem cell , Spinal cord injury – H0005513	17
4.4.16.	Wharton’s Jelly derived mesenchymal stem cell , Stargardt disease – H0005514	17

5. Scientific Advice 17

5.1.	New requests – appointment of CAT Rapporteurs	17
5.2.	CAT reports.....	17
5.3.	List of Issues	17
5.4.	Finalisation of SA procedures	17

6. Pre-Authorisation Activities 17

6.1.	Paediatric investigation plans.....	17
6.2.	ITF briefing meetings in the field of ATMPs	17
6.3.	Priority Medicines (PRIME) – Eligibility requests.....	17
6.3.1.	Month 0 - Start of the procedure	18
6.3.2.	Month 1 – Discussion of eligibility	18
6.3.3.	Month 2 – Recommendation of eligibility.....	18

7. Organisational, regulatory and methodological matters 18

7.1.	Mandate and organisation of the CAT	18
7.1.1.	Preparation for election of CAT Chair.....	18
7.1.2.	Strategic Review & Learning meeting (SRLM) – Helsinki, Finland, 21 – 22 November 2019	18
7.1.3.	Strategic Review & Learning meeting – joint CAT/Clinical trial facilitation group (CTFG), Bucharest, Romania, June 2019	18
7.1.4.	CAT plenary 22-24 January 2020: practical arrangements in the new building.....	18
7.2.	Coordination with EMA Scientific Committees.....	18
7.2.1.	Committee for Medicinal Products for Human Use (CHMP).....	19
7.3.	Coordination with EMA Working Parties/Working Groups/Drafting Groups	19
7.3.1.	Working Party with Patients’ and Consumers’ Organisations (PCWP) and Working Party with Healthcare Professionals’ Organisations (HCPWP)	19
7.4.	Cooperation within the EU regulatory network.....	19
7.4.1.	Questions & Answers on comparability	19
7.5.	Cooperation with international regulators	19
7.5.1.	ATMP cluster teleconference with FDA-USA, Health Canada and PMDA-Japan	19
7.5.2.	International council for harmonisation of technical requirements for pharmaceuticals for human use (ICH) S12 – guideline on non-clinical biodistribution considerations for gene therapy	19
7.5.3.	International Pharmaceutical Regulators Programme (IPRP) – Cell therapy working group	20
7.6.	CAT work plan	20
7.6.1.	CAT work plan 2020.....	20

7.7.	Planning and reporting	20
7.7.1.	Planning estimates of forthcoming ATMP MAAs	20
7.8.	Others	20
7.8.1.	CAT regulatory session at the 2019 Annual Congress of the European Society of Gene and Cell Therapy (ESGCT), 25 October 2019, Barcelona (Spain)	20
7.8.2.	Presence of nitrosamine impurities in human medicinal products containing chemically synthesised active pharmaceutical ingredients.....	20
8.	Any other business	21
8.1.	EMA's move to the permanent building, Zuid district, Amsterdam, The Netherlands	21
9.	Explanatory notes	22
10.	List of participants	26

1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

In accordance with the Agency's policy on handling of declarations of interests of scientific committees' members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and based on the topics in the agenda of the current meeting, the Committee Secretariat announced that no restriction in the involvement of meeting participants in upcoming discussions was identified.

Participants in this meeting were asked to declare any changes, omissions or errors to their declared interests and/or additional restrictions concerning the matters for discussion. No new or additional interests or restrictions were declared.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure and as included in the list of participants. All decisions taken at this meeting were made in the presence of a quorum of members (i.e. 22 or more members were present in the room). All decisions, recommendations and advice were agreed by consensus, unless otherwise specified.

1.2. Adoption of agenda

The CAT agenda for 04-06 December 2019 meeting was adopted.

1.3. Adoption of the minutes

The CAT minutes for 06-08 November 2019 meeting were adopted with some editorial comments.

2. Evaluation of ATMPs

2.1. Opinions

No items

2.2. Oral explanations

No items

2.3. Day 180 list of outstanding issues

2.3.1. Onasemnogene abeparvovec - Orphan - EMEA/H/C/004750

AveXis Netherlands B.V.; treatment of spinal muscular atrophy (SMA)

Scope: D180 LoOIs

Action: for adoption

List of Outstanding Issues adopted on 21.06.2019. List of Questions adopted on 22.02.2019.

The Rapporteur presented the joint response assessment report. A second list of outstanding issues was presented.

CAT adopted the second list of outstanding issues.

2.4. Day 120 list of questions

No items

2.5. Day 80 assessment reports

No items

2.6. Update on ongoing initial applications

No items

2.7. New applications

- 2.7.1. Autologous CD34+ cell enriched population that contains hematopoietic stem and progenitor cells transduced ex vivo using a lentiviral vector encoding the human arylsulfatase a gene - Orphan - EMEA/H/C/005321
-

Accelerated assessment

Orchard Therapeutics Limited; treatment of metachromatic leukodystrophy (MLD)

Scope: Timetable for assessment

Action: for adoption

The timetable was adopted.

2.8. Withdrawal of initial marking authorisation application

No items

2.9. Re-examination of initial application procedures under Article 9(2) of Regulation No. 726/2004

No items

2.10. GMP and GCP inspections requests

No items

2.11. Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

2.11.1. Alofisel - darvadstrocel - Orphan - EMEA/H/C/004258/II/0010/G

Takeda Pharma A/S

Rapporteur: Lisbeth Barkholt

Scope: quality: RSI

Action: for adoption

The RSI was adopted.

2.11.2. Kymriah - tisagenlecleucel - Orphan - EMEA/H/C/004090/II/0013/G

Novartis Europharm Limited

Rapporteur: Rune Kjekken, CHMP Coordinator: Ingrid Wang, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: safety: RSI

Group of variations consisting of:

1) C.I.4: a type II variation to update sections 4.4, 4.8, 5.1 and 5.2 of the SmPC with the long-term efficacy and safety of Kymriah in relapsed/refractory DLBCL based on the 24 months follow-up results from study CCTL019C2201.

2) C.I.4: a type II variation to update of sections 4.4, 4.8, 5.1 and 5.2 of the SmPC based on interim results from study CCTL019B2202.

3) C.I.4: a type II variation to update section 5.2 of the SmPC based on interim results from study CCTL019B2205J.

The Annex II and the Package Leaflet are updated accordingly. In addition, the Marketing authorisation holder (MAH) took the opportunity to clarify the wording of the indication in order to reflect that patients of 25 years of age are being included and to introduce some minor editorial corrections throughout the SmPC and the Package Leaflet. The RMP version 2.0 has also been submitted.

Action: for adoption

See also 2.12.1.

CAT discussed the outcome of the variation. A rewording of the SmPC was proposed. The RSI was adopted.

2.12. Other Post-Authorisation Activities

2.12.1. Kymriah - tisagenlecleucel - Orphan - EMEA/H/C/004090/X/0010

Novartis Europharm Limited

Rapporteur: Rune Kjekken, CHMP Coordinator: Ingrid Wang, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: quality: Opinion

Extension application

Action: for adoption

See also 2.11.2.

CAT adopted the opinion of the extension application.

2.12.2. [Strimvelis - autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence - Orphan - EMEA/H/C/003854/ANX/004.2](#)

Orchard Therapeutics (Netherlands) BV

Rapporteur: Sol Ruiz, CHMP Coordinator: Maria Concepcion Prieto Yerro

Scope: Opinion

PASS interim study report: Adenosine Deaminase Severe Combined Immunodeficiency (ADA-SCID) Registry for Patients Treated with Strimvelis™ (or GSK2696273) Gene Therapy: Long-Term Prospective, Non-Interventional Follow-up of Safety and Effectiveness.

Action: for adoption

Further to CAT discussion in November 2019 (see CAT November minutes, agenda point 2.12.2), PRAC re-discussed their assessment of the PAM. CAT adopted the PAM assessment.

2.12.3. [Zynteglo - autologous CD34+ cell enriched population that contains hematopoietic stem cells transduced with lentiglobin BB305 lentiviral vector encoding the beta-A-T87Q-globin gene - Orphan - EMEA/H/C/003691/REC/007](#)

bluebird bio (Netherlands) B.V

Rapporteur: Carla Herberts, CHMP Coordinator: Paula Boudewina van Hennik

Scope: quality: Opinion

Action: for adoption

See also 2.12.4.

The PAM assessment was adopted.

2.12.4. [Zynteglo - autologous CD34+ cell enriched population that contains hematopoietic stem cells transduced with lentiglobin BB305 lentiviral vector encoding the beta-A-T87Q-globin gene - Orphan - EMEA/H/C/003691/REC/008](#)

bluebird bio (Netherlands) B.V

Rapporteur: Carla Herberts, CHMP Coordinator: Paula Boudewina van Hennik

Scope: quality: Opinion

Action: for adoption

See also 2.12.3.

The PAM assessment was adopted.

3. Certification of ATMPs

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

3.1. Opinion

No items

3.2. Day 60 Evaluation Reports

No items

3.3. New Applications

No items

4. Scientific Recommendation on Classification of ATMPs

4.1. New requests – Appointment of CAT Coordinator

Recombinant adeno-associated viral vector (serotype 5 capsid) carrying an optimized human rhodopsin kinase promoter (hRKp) and a shortened human retinitis pigmentosa GTPase regulator (hRPGR) gene flanked by the ITRs of AAV serotype 2 – Intended for the treatment of X-linked Retinitis Pigmentosa owing to defects in the RPGR

Scope: appointment of CAT Coordinator and adoption of timetable

Action: for adoption

The CAT coordinator was appointed.

4.1.1. Recombinant adeno-associated viral vector serotype 9 encoding a codon-optimised human aspartylglucosaminidase (AGA) transgene –

Intended for the treatment of Aspartylglucosaminuria

Scope: appointment of CAT Coordinator and adoption of timetable

Action: for adoption

The CAT coordinator was appointed.

4.1.2. Adipose tissue derived mesenchymal stem cell , Alopecia -

Intended for the treatment of alopecia

Scope: appointment of CAT Coordinator and adoption of timetable

Action: for adoption

The CAT coordinator was appointed.

4.1.3. Wharton's Jelly derived mesenchymal stem cell , AMD -

Intended for the treatment of age-related macular degeneration (AMD)

Scope: appointment of CAT Coordinator and adoption of timetable

Action: for adoption

The CAT coordinator was appointed.

4.1.4. Wharton's Jelly derived mesenchymal stem cell , bone non-union -

Intended for the treatment of bone non-union

Scope: appointment of CAT Coordinator and adoption of timetable

Action: for adoption

The CAT coordinator was appointed.

4.1.5. Wharton's Jelly derived mesenchymal stem cell , Chorioretinal disorders -

Intended for the treatment of Behçet's disease, Choroideremia, Vitelliform macular dystrophy (Best disease), Cone rod dystrophies

Scope: appointment of CAT Coordinator and adoption of timetable

Action: for adoption

The CAT coordinator was appointed.

4.1.6. Wharton's Jelly derived mesenchymal stem cell , Epidermolysis bullosa -

Intended for the treatment of Epidermolysis bullosa

Scope: appointment of CAT Coordinator and adoption of timetable

Action: for adoption

The CAT coordinator was appointed.

4.1.7. Adipose tissue derived mesenchymal stem cell , Hypertrophic scars -

Intended for the treatment of hypertrophic scars

Scope: appointment of CAT Coordinator and adoption of timetable

Action: for adoption

The CAT coordinator was appointed.

4.1.8. Wharton's Jelly derived mesenchymal stem cell , hypoxic-ischemic encephalopathy (HIE) -

Intended for the treatment of hypoxic-ischemic encephalopathy

Scope: appointment of CAT Coordinator and adoption of timetable

Action: for adoption

The CAT coordinator was appointed.

4.2. Day 30 ATMP scientific recommendation

4.2.1. Autologous chondrocytes in suspension - H0005498

Intended for the treatment of knee joint cartilage lesion

Scope: ATMP scientific recommendation

Action: for adoption

CAT discussed the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 20 December 2019.

The CAT recommendation will be considered final if no comments are received from the European Commission. The final report will be sent thereafter to the applicant.

4.2.2. Autologous chondrocytes on a fibrinogen carrier – H0005525

Intended for the treatment of knee joint cartilage lesion

Scope: ATMP scientific recommendation

Action: for adoption

CAT discussed the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 20 December 2019.

The CAT recommendation will be considered final if no comments are received from the European Commission. The final report will be sent thereafter to the applicant.

4.2.3. MICs - Modulated immune cells – H0005515

Intended for prophylactic use in solid organ transplantation (e.g. kidney transplantation) and therapeutic use in autoimmune disease (e.g. multiple sclerosis)

Scope: ATMP scientific recommendation

Action: for adoption

CAT discussed the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 20 December 2019.

The CAT recommendation will be considered final if no comments are received from the European Commission. The final report will be sent thereafter to the applicant.

4.2.4. Wharton's Jelly derived mesenchymal stem cell , Adrenoleukodystrophy – H0005526

Intended for the treatment of adrenoleukodystrophy

Scope: ATMP scientific recommendation

Action: for adoption

CAT discussed the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 20 December 2019.

The CAT recommendation will be considered final if no comments are received from the European Commission. The final report will be sent thereafter to the applicant.

4.2.5. Wharton's Jelly derived mesenchymal stem cell , Encephalopathy – H0005527

Intended for the treatment of encephalopathy

Scope: ATMP scientific recommendation

Action: for adoption

CAT discussed the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 20 December 2019.

The CAT recommendation will be considered final if no comments are received from the European Commission. The final report will be sent thereafter to the applicant.

4.2.6. Wharton's Jelly derived mesenchymal stem cell , Epilepsy – H0005528

Intended for the treatment of epilepsy

Scope: ATMP scientific recommendation

Action: for adoption

CAT discussed the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 20 December 2019.

The CAT recommendation will be considered final if no comments are received from the European Commission. The final report will be sent thereafter to the applicant.

4.2.7. Wharton's Jelly derived mesenchymal stem cell , Osteoarthritis – H0005529

Intended for the treatment of osteoarthritis

Scope: ATMP scientific recommendation

Action: for adoption

CAT discussed the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 20 December 2019.

The CAT recommendation will be considered final if no comments are received from the European Commission. The final report will be sent thereafter to the applicant.

4.2.8. Wharton's Jelly derived mesenchymal stem cell , Polyneuropathy – H0005530

Intended for the treatment of polyneuropathy

Scope: ATMP scientific recommendation

Action: for adoption

CAT discussed the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 20 December 2019.

The CAT recommendation will be considered final if no comments are received from the European Commission. The final report will be sent thereafter to the applicant.

4.2.9. Wharton's Jelly derived mesenchymal stem cell , Spinal muscular atrophy – H0005531

Intended for the treatment of spinal muscular atrophy

Scope: ATMP scientific recommendation

Action: for adoption

CAT discussed the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 20 December 2019.

The CAT recommendation will be considered final if no comments are received from the European Commission. The final report will be sent thereafter to the applicant.

4.2.10. Wharton's Jelly derived mesenchymal stem cell , Spinocerebellar ataxia – H0005532

Intended for the treatment of spinocerebellar ataxia

Scope: ATMP scientific recommendation

Action: for adoption

CAT discussed the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 20 December 2019.

The CAT recommendation will be considered final if no comments are received from the European Commission. The final report will be sent thereafter to the applicant.

4.3. Day 60 revised scientific recommendation (following list of questions)

No items

4.4. Finalisation of procedure

4.4.1. Recombinant adeno associated viral vector serotype 9 containing the human CLN6 gene Amicus – H0005491

Intended for the treatment of neuronal ceroid lipofuscinosis type 6 (CLN6) disease (CLN6 Batten disease)

Scope: no comments raised by the European Commission. Final ATMP scientific recommendation

Action: for information

The information was noted.

4.4.2. Recombinant adeno associated viral vector serotype 9 containing the human CLN3 gene – H0005492

Intended for the treatment of neuronal ceroid lipofuscinosis type 3 (CLN3) disease (CLN3 Batten disease)

Scope: no comments raised by the European Commission. Final ATMP scientific recommendation

Action: for information

The information was noted.

4.4.3. Wharton's Jelly derived mesenchymal stem cell , Alopecia areata – H0005494

Intended for the treatment of alopecia areata

Scope: no comments raised by the European Commission. Final ATMP scientific recommendation

Action: for information

The information was noted.

4.4.4. [Wharton's Jelly derived mesenchymal stem cell , Pervasive developmental disorder – H0005502](#)

Intended for the treatment of pervasive developmental disorder

Scope: no comments raised by the European Commission. Final ATMP scientific recommendation

Action: for information

The information was noted.

4.4.5. [Wharton's Jelly derived mesenchymal stem cell , Cerebral infarction – H0005503](#)

Intended for the treatment of cerebral infarction

Scope: no comments raised by the European Commission. Final ATMP scientific recommendation

Action: for information

The information was noted.

4.4.6. [Wharton's Jelly derived mesenchymal stem cell , Development delay – H0005504](#)

Intended for the treatment of development delay

Scope: no comments raised by the European Commission. Final ATMP scientific recommendation

Action: for information

The information was noted.

4.4.7. [Wharton's Jelly derived mesenchymal stem cell , Diabetes - H0005505](#)

Intended for the treatment of diabetes

Scope: no comments raised by the European Commission. Final ATMP scientific recommendation

Action: for information

The information was noted.

4.4.8. [Wharton's Jelly derived mesenchymal stem cell , Muscular dystrophy – H0005506](#)

Intended for the treatment of muscular dystrophy

Scope: no comments raised by the European Commission. Final ATMP scientific recommendation

Action: for information

The information was noted.

4.4.9. [Wharton's Jelly derived mesenchymal stem cell , Endometrial atrophy – H0005507](#)

Intended for the treatment of endometrial atrophy

Scope: no comments raised by the European Commission. Final ATMP scientific recommendation

Action: for information

The information was noted.

4.4.10. Wharton's Jelly derived mesenchymal stem cell , Multiple sclerosis – H0005508

Intended for the treatment of multiple sclerosis

Scope: no comments raised by the European Commission. Final ATMP scientific recommendation

Action: for information

The information was noted.

4.4.11. Wharton's Jelly derived mesenchymal stem cell , Optic neuropathy – H0005509

Intended for the treatment of optic neuropathy

Scope: no comments raised by the European Commission. Final ATMP scientific recommendation

Action: for information

The information was noted.

4.4.12. Wharton's Jelly derived mesenchymal stem cell , Premature ovarian failure – H0005510

Intended for the treatment of premature ovarian failure

Scope: no comments raised by the European Commission. Final ATMP scientific recommendation

Action: for information

The information was noted.

4.4.13. Wharton's Jelly derived mesenchymal stem cell , Retinitis pigmentosa – H0005511

Intended for the treatment of retinitis pigmentosa

Scope: no comments raised by the European Commission. Final ATMP scientific recommendation

Action: for information

The information was noted.

4.4.14. Wharton's Jelly derived mesenchymal stem cell , Spina bifida – H0005512

Intended for the treatment of spinal bifida

Scope: no comments raised by the European Commission. Final ATMP scientific recommendation

Action: for information

The information was noted.

4.4.15. Wharton's Jelly derived mesenchymal stem cell , Spinal cord injury – H0005513

Intended for the treatment of spinal cord injury

Scope: no comments raised by the European Commission. Final ATMP scientific recommendation

Action: for information

The information was noted.

4.4.16. Wharton's Jelly derived mesenchymal stem cell , Stargardt disease – H0005514

Intended for the treatment of Stargardt disease

Scope: no comments raised by the European Commission. Final ATMP scientific recommendation

Action: for information

The information was noted.

5. Scientific Advice

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

5.1. New requests – appointment of CAT Rapporteurs

5.2. CAT reports

5.3. List of Issues

5.4. Finalisation of SA procedures

6. Pre-Authorisation Activities

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

6.1. Paediatric investigation plans

No items

6.2. ITF briefing meetings in the field of ATMPs

No items

6.3. Priority Medicines (PRIME) – Eligibility requests

- 6.3.1. Month 0 - Start of the procedure
 - 6.3.2. Month 1 – Discussion of eligibility
 - 6.3.3. Month 2 – Recommendation of eligibility
-

7. Organisational, regulatory and methodological matters

7.1. Mandate and organisation of the CAT

7.1.1. Preparation for election of CAT Chair

Scope: procedure and timelines for the election of the CAT chair to take place on 24 January 2020

Action: for information.

The information was noted.

7.1.2. Strategic Review & Learning meeting (SRLM) – Helsinki, Finland, 21 – 22 November 2019

CAT: Martina Schübler-Lenz, Heli Suila

Scope: feedback from the meeting that took place on 21-22 November 2019

Action: for discussion

Feedback was provided from the discussion at the SRLM that took place in Helsinki on 21-22 November 2019.

7.1.3. Strategic Review & Learning meeting – joint CAT/Clinical trial facilitation group (CTFG), Bucharest, Romania, June 2019

CAT: Simona Badoi

Scope: minutes from the SRLM meeting

Action: for adoption

CAT adopted the minutes of the SRLM that took place in Bucharest in June 2019.

7.1.4. CAT plenary 22-24 January 2020: practical arrangements in the new building

Scope: change to the start time of the meeting

Action: for information

The information was noted.

See also 8.1

7.2. Coordination with EMA Scientific Committees

7.2.1. Committee for Medicinal Products for Human Use (CHMP)

Scope: Summary of Outcomes (SoO) for the November 2019 meeting

Action: for information

The information was noted.

7.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

7.3.1. Working Party with Patients' and Consumers' Organisations (PCWP) and Working Party with Healthcare Professionals' Organisations (HCPWP)

Scope:

-Meeting Summary PCWP Plenary Meeting 24 Sep 2019

-Meeting Summary HCPWP Plenary Meeting 24 Sep 2019

-Meeting Summary PCWP/HCPWP Joint Meeting 25 Sep 2019

-Agenda for the Annual PCWP/HCPWP meeting with all eligible organisations, 20 November 2019

Action: for information

The information was noted.

7.4. Cooperation within the EU regulatory network

7.4.1. Questions & Answers on comparability

CAT drafting group: Margarida Menezes, Ilona Reischl, Ivana Haunerová, Heli Suila, Barbara Bonamassa

Scope: draft questions and answers document

Action: for adoption

The Q&A on comparability, incorporating the comment received, was discussed and agreed by BWP during their December meeting. The final Q&A was presented to CAT and adopted. The Q&A will be published on the EMA webpage. In parallel with the publication, the document will be sent to FDA, Health Canada, PMDA and Swiss Medic.

7.5. Cooperation with international regulators

7.5.1. ATMP cluster teleconference with FDA-USA, Health Canada and PMDA-Japan

Scope: feedback on the teleconference that took place on Thursday 14 November 2019.

Action: for information

Feedback was provided from the discussion at the November ATMP cluster TC.

7.5.2. International council for harmonisation of technical requirements for pharmaceuticals for human use (ICH) S12 – guideline on non-clinical biodistribution considerations for gene therapy

CAT: Claire Beuneu, Rune Kjeklen

Scope: draft concept paper proposal and business plan. Feedback from discussion at the ICH management board meeting on 18 November 2019

Action: for information

Feedback was provided from the ICH discussion on the S12 guideline. It was agreed that the first version of the document will be circulated to CAT; CAT members are asked for their active input / support on the draft.

7.5.3. International Pharmaceutical Regulators Programme (IPRP) – Cell therapy working group

CAT: Ivana Haunerová

Scope: feedback on the teleconference that took place on 21 November 2019

Action: for information

Ivana Haunerová provided feedback from the discussions during the IPRP cell therapy working group teleconference. There was a short discussion on the 3 proposals for new projects.

7.6. CAT work plan

7.6.1. CAT work plan 2020

CAT: Martina Schübler-Lenz

Scope: draft work plan 2020

Action: for adoption

The CAT work plan for 2020 was discussed.

The CAT work plan will be adopted at the January 2020 CAT meeting.

7.7. Planning and reporting

7.7.1. Planning estimates of forthcoming ATMP MAAs

Scope: Q4/2019 update of the business pipeline report for the human scientific committees

Action: for information

The information was noted.

7.8. Others

7.8.1. CAT regulatory session at the 2019 Annual Congress of the European Society of Gene and Cell Therapy (ESGCT), 25 October 2019, Barcelona (Spain)

CAT: Martina Schüssler-Lenz, Jan Müller-Berghaus, Anne Pastoft, Heli Suila

Scope: feedback on the CAT session at the ESGCT annual congress

Action: for information

The CAT chair provided feedback from the CAT regulatory session at the ESGCT congress.

7.8.2. Presence of nitrosamine impurities in human medicinal products containing chemically synthesised active pharmaceutical ingredients

MAHs: various

Scope: presentation of the issue and steps taken

Action: for information

Topic postponed until the January 2020 CAT meeting.

8. Any other business

8.1. EMA's move to the permanent building, Zuid district, Amsterdam, The Netherlands

Scope: information about the building, transport and hotels and the first day in the new premises

Action: for information

The information was noted.

See also 7.1.4

Date of next CAT meeting:

22-24/01/2020

9. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

Abbreviations / Acronyms

AAV: Adeno-Associated Virus

AR: Assessment Report

ATMP: Advanced Therapy Medicinal Product

BWP: Biologics Working Party

CAT: Committee for Advanced Therapies

CHMP: Committee for Medicinal Product for Human Use

COMP: Committee for Orphan Medicinal Products

CTFG: Clinical Trial Facilitation Group

DG: Drafting Group

EC: European Commission

ERA: Environmental Risk Assessment

FDA: Food and Drug Administration

FL: Final Letter

GCG: Guideline Consistency Group

GCP: Good Clinical Practice

GLP: Good Laboratory Practice

GMO: Genetically-modified organism

GMP: Good Manufacturing Practice

GTMP: Gene Therapy Medicinal Product

HTA: Health Technology Assessment Bodies

HSPC: Hematopoietic Stem and Progenitor Cells

ITF: Innovative Task Force

JR: Joint Report

LoOI: List of outstanding issues

LoQ: List of questions

MA: Marketing Authorisation

MAA: Marketing Authorisation Application

MAH: Marketing Authorisation Holder

MSC: Mesenchymal stem cells

PDCO: Paediatric Committee

PMDA: Pharmaceuticals and Medical Devices Agency (Japan)

PIP: Paediatric Investigation Plan

PL: Package leaflet

PRAC: Pharmacovigilance and Risk Assessment Committee #

PRIME: Priority Medicines

RMP: Risk Management Plan

RP: Reflection paper
 RSI: Request for supplementary information
 SAs: Scientific Advices
 SAG-O: Scientific Advisory Group Oncology
 SAWP: Scientific Advice Working Party
 SR: Summary Report
 SWP: Scientific Working Party
 SME: Small and medium size enterprises
 SmPC: Summary of Products Characteristics
 TT: Timetable


Evaluation of ATMPs (section 2)

This section lists applications for marketing authorisations of new Advanced Therapy Medicinal Products (ATMPs) that are to be discussed by the Committee. It also lists any ATMP related inspection requests (section 2.9) and Post-authorisation activities (section 2.10).

New applications (sections 2.1. to 2.12.)

Section 2.1 is for ATMPs nearing the end of the evaluation and for which the CAT is expected to adopt a draft **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CAT opinion is transmitted to the CHMP for final adoption. The CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU. More information on the evaluation of ATMPs can be found [here](#).

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CAT. The clock stop happens after day 120 and may also happen after day 180, when the CAT has adopted respectively a **Day 120 list of questions** (section 2.3) or a List of outstanding issues to be addressed by the company, which is listed in the agenda under sections 2.7 (**Ongoing evaluation procedures**). Section 2.7 also includes the CAT discussions at any other timepoint of the evaluation procedure of new applications.

Oral explanation (section 2.2.)

Prior to adoption of the CAT opinion, marketing authorisation applicants are normally invited to the CAT plenary meeting to address questions raised by the Committee.

Oral explanations normally relate to ongoing applications, but they can also relate to any other issue for which the CAT would like to discuss with company representatives in person.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 (section

2.6.)

This section lists applications for new marketing authorisation for ATMPs for which the applicant has requested a re-examination of the opinion previously issued by the CHMP. Similar to the initial evaluation of a marketing authorisation of an ATMP, CAT will adopt a draft re-examination opinion, which is transmitted to the CHMP for final adoption.

Withdrawal of applications (section 2.7.)

This section includes information on marketing authorisation applications that are withdrawn by the applicant. Applicants may decide to withdraw applications at any stage during the assessment and a CAT opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

New applications (section 2.9.)

In this section, information is included on upcoming marketing authorisation applications for ATMPs, as well as information on appointment of Rapporteurs for new ATMP applications.

GMP and GCP Inspections Issues (section 2.10.)

This section lists inspections that are undertaken for ATMPs. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Post-authorisation activities (section 2.12.)

This section lists type II variations, extension application according to Annex I of Reg. 1234/2008, re-examination procedures for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP and other issues concerning authorised medicines that are not covered elsewhere in the agenda such as annual reassessments, 5-year renewals, supply shortages, quality defects. Issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines, will also be included here.

Certification of ATMPs (section 3)

This section includes the scientific evaluation by the CAT of quality and non-clinical data that small and medium-sized enterprises have generated at any stage of the ATMP development process. More information on the ATMP certification procedure can be found [here](#).

Scientific Recommendation on Classification of ATMPs (Section 4)

This section includes the scientific recommendation by the CAT on whether medicines based on genes, cells or tissues meet the scientific criteria that define ATMPs. More information on the ATMP classification procedure, including the outcomes of finalised classifications, can be found [here](#).

Scientific Advice (section 5)

This section includes all scientific advice given to companies during the development of an ATMP. Information related to the number of ATMP related scientific advices discussed by CAT can be found in the CAT Monthly reports. Further information on SAWP can be found [here](#).

Pre-Authorisation (section 6)

Paediatric Investigation Plan (PIP)

This section includes the discussion of an ATMP before a formal application for marketing authorisation is submitted. These cases refer for example to requests for an accelerated assessment for medicines

that are of major interest for public health or can be considered a therapeutic innovation: in case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

CAT contributes to the evaluation of a Paediatric Investigation Plan (PIPs) for ATMPs by the Paediatric Committee. These PIPs are included in this section of the Agenda.

ITF Briefing meeting in the field of ATMPs

This section refers to briefing meetings of the Innovation Task Force and International co-operations activities of the CAT

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes of meetings with applicants developing ATMPs and of other ITF meetings of interest to the CAT are included in this section of the agenda. Further information on the ITF can be found [here](#).

Priority Medicines (PRIME)

This section includes the new requests for eligibility to PRIME for ATMPs under development, the discussions in CAT of these eligibility requests and the final recommendations for eligibility of ATMPs adopted by CHMP.

CAT will appoint one of its members as the CAT sponsor for each new ATMP eligibility request who will lead the CAT discussion based on the recommendation from the SAWP.

Organisational, regulatory and methodological matters (section 7)

This section includes topics related to regulatory and procedural guidance, CAT workplan, CAT meeting organisation (including CAT membership), planning and reporting, co-ordination with other committees, working parties and scientific advisory groups.

Furthermore, this section refers to the activities of the CAT drafting groups developing scientific guidelines for gene therapy medicinal products and for cell-based medicinal products, cooperation within the EU regulatory network and international regulators as well as direct interaction with interested parties. It also includes topics of scientific interest for the Committee that are not directly related to the work of the CAT drafting groups or CAT associated working parties.

Any other business (section 8)

This section is populated with miscellaneous topics not suitable under the previous headings.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/

10. List of participants

including any restrictions with respect to involvement of members / alternates / experts following evaluation of declared interests for the 04-06 December 2019 meeting.

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Martina Schüssler-Lenz	Chair	Germany	No interests declared	
Ilona Reischl	Member	Austria	No interests declared	
Claire Beuneu	Member	Belgium	No interests declared	
Belaïd Sekkali	Alternate	Belgium	No interests declared	
Evelina Shumkova	Alternate	Bulgaria	No interests declared	
Mirna Golemovic	Member	Croatia	No interests declared	
Rafaella Pontou	Member	Cyprus	No interests declared	
Ivana Haunerova	Member	Czech Republic	No interests declared	
Ondrej Palan	Alternate	Czech Republic	No interests declared	
Anne Pastoft	Member	Denmark	No interests declared	
Pille Saalik	Alternate	Estonia	No interests declared	
Heli Suila	Member	Finland	No interests declared	
Olli Tenhunen	Alternate	Finland	No interests declared	
Violaine Closson	Member	France	No interests declared	
Nathalie Morgensztejn	Alternate	France	No interests declared	
Jan Mueller-Berghaus	Member (CHMP co-opted member)	Germany	No interests declared	
Egbert Flory	Alternate (to CHMP representative)	Germany	No interests declared	
Asterios Tsiftoglou	Member	Greece	No interests declared	
Katalin Lengyel	Member	Hungary	No interests declared	
Maura O'Donovan	Member	Ireland	No interests declared	
Paolo Gasparini	Member	Italy	No interests declared	
Una Riekstina	Member	Latvia	No interests declared	
Romaldas Mačiulaitis	Member (CHMP member)	Lithuania	No interests declared	
Guy Berchem	Member (to CHMP representative)	Luxembourg	No restrictions applicable to this meeting	
Anthony	Alternate (to	Malta	No interests declared	

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Samuel	CHMP representative)			
Carla Herberts	Member	Netherlands	No interests declared	
Johannes Hendrikus Ovelgonne	Alternate	Netherlands	No interests declared	
Rune Kjeklen	Member	Norway	No restrictions applicable to this meeting	
Maja Sommerfelt Grønvold	Alternate	Norway	No restrictions applicable to this meeting	
Dariusz Śladowski	Member	Poland	No restrictions applicable to this meeting	
Margarida Menezes-Ferreira	Alternate (to CHMP representative)	Portugal	No interests declared	
Simona Badoi	Member	Romania	No interests declared	
Lukas Slovak	Member	Slovakia	No interests declared	
Metoda Lipnik-Stangelj	Member	Slovenia	No interests declared	
Sol Ruiz	Member (CHMP co-opted member)	Spain	No interests declared	
Marcos Timón	Alternate (to CHMP representative)	Spain	No interests declared	
Lisbeth Barkholt	Member	Sweden	No interests declared	
Louise Bisset	Alternate	United Kingdom	No interests declared	
Bernd Gänsbacher	Member	Healthcare Professionals' Representative	No interests declared	
Alessandro Aiuti	Member	Healthcare Professionals' Representative	No restrictions applicable to this meeting	
Alessandra Renieri	Alternate	Healthcare Professionals' Representative	No interests declared	
Kerstin Sollerbrant	Member	Patients' Representative	No interests declared	
Kieran Breen	Member	Patients' Representative	No restrictions applicable to this meeting	

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Barbara Bonamassa	Expert - in person*	AIFA-IT	No interests declared	
Jan Span	Expert - in person*	CBG-MEB, NL	No interests declared	
Marja van de Bovenkamp	Expert - in person*	CBG-MEB, NL	No interests declared	
Janneke van Leeuwen	Expert - in person*	CBG-MEB, NL	No interests declared	
Hans Hillege	Expert - via telephone*	CBG-MEB, NL	No interests declared	
Ulla Liminga	Expert - via telephone*	MPA-SE	No interests declared	
Juliane Rau	Expert - via telephone*	PEI-DE	No interests declared	
Beate Mosl	Expert - via telephone*	PEI-DE	No restrictions applicable to this meeting	
Tiina Palomaki	Expert - via telephone*	FIMEA-FI	No interests declared	
Andreea Barbu	Expert - via telephone*	MPA-SE	No restrictions applicable to this meeting	
A representative from the European Commission attended the meeting				
Meeting run with support from relevant EMA staff				

* Experts were only evaluated against the agenda topics or activities they participated in.